Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Hepatitis C

  Free Subscription


Articles published in PLoS One

Retrieve available abstracts of 144 articles:
HTML format



Single Articles


    January 2022
  1. MAWATARI S, Kumagai K, Oda K, Tabu K, et al
    Features of patients who developed hepatocellular carcinoma after direct-acting antiviral treatment for hepatitis C Virus.
    PLoS One. 2022;17:e0262267.
    PubMed     Abstract available


  2. BOODRAM B, Mackesy-Amiti ME, Khanna A, Brickman B, et al
    People who inject drugs in metropolitan Chicago: A meta-analysis of data from 1997-2017 to inform interventions and computational modeling toward hepatitis C microelimination.
    PLoS One. 2022;17:e0248850.
    PubMed     Abstract available


  3. BALIASHVILI D, Averhoff F, Kasradze A, Salyer SJ, et al
    Risk factors and genotype distribution of hepatitis C virus in Georgia: A nationwide population-based survey.
    PLoS One. 2022;17:e0262935.
    PubMed     Abstract available


  4. MORSICA G, Galli L, Messina E, Castagna A, et al
    Risk of HIV viral rebound in HIV infected patients on direct acting antivirals (DAAs) treatment for HCV.
    PLoS One. 2022;17:e0262917.
    PubMed     Abstract available


  5. PRINSENBERG T, Illidge J, Zantkuijl P, Bedert M, et al
    Usability, acceptability, and self-reported impact of an innovative hepatitis C risk reduction intervention for men have sex with men: A mixed methods study.
    PLoS One. 2022;17:e0263654.
    PubMed     Abstract available


  6. LIM SH, Lee S, Lee YB, Lee CH, et al
    Increased prevalence of transfusion-transmitted diseases among people with tattoos: A systematic review and meta-analysis.
    PLoS One. 2022;17:e0262990.
    PubMed     Abstract available


  7. SHRESTHA LB, Yadav GK, Pradhan S, Sharma A, et al
    Co-infection of Hepatitis B and Hepatitis C among HIV-infected patients: A cross-sectional study from tertiary care hospital of eastern Nepal.
    PLoS One. 2022;17:e0264791.
    PubMed     Abstract available


  8. TATARA E, Gutfraind A, Collier NT, Echevarria D, et al
    Modeling hepatitis C micro-elimination among people who inject drugs with direct-acting antivirals in metropolitan Chicago.
    PLoS One. 2022;17:e0264983.
    PubMed     Abstract available


  9. TRAN L, Jung J, Feldman R, Riley T 3rd, et al
    Disparities in the quality of care for chronic hepatitis C among Medicare beneficiaries.
    PLoS One. 2022;17:e0263913.
    PubMed     Abstract available


  10. NAGORNYKH AM, Tyumentseva MA, Tyumentsev AI, Akimkin VG, et al
    Protocol for chronic hepatitis B virus infection mouse model development by patient-derived orthotopic xenografts.
    PLoS One. 2022;17:e0264266.
    PubMed     Abstract available


  11. TAKAURA K, Kurosaki M, Inada K, Kirino S, et al
    The impact of background liver disease on the long-term prognosis of very-early-stage HCC after ablation therapy.
    PLoS One. 2022;17:e0264075.
    PubMed     Abstract available


  12. LIN MC, Dai CY, Huang CF, Yeh ML, et al
    Itemization difference of patient-reported outcome in patients with chronic liver disease.
    PLoS One. 2022;17:e0264348.
    PubMed     Abstract available


  13. YAZDANI K, Dolguikh K, Zhang W, Shayegi-Nik S, et al
    Knowledge of hepatitis C and awareness of reinfection risk among people who successfully completed direct acting antiviral therapy.
    PLoS One. 2022;17:e0265811.
    PubMed     Abstract available



  14. Expression of Concern: Interferon and Ribavirin Combination Treatment Synergistically Inhibit HCV Internal Ribosome Entry Site Mediated Translation at the Level of Polyribosome Formation.
    PLoS One. 2022;17:e0266498.
    PubMed    



  15. Expression of Concern: SH2 Modified STAT1 Induces HLA-I Expression and Improves IFN-gamma Signaling in IFN-alpha Resistant HCV Replicon Cells.
    PLoS One. 2022;17:e0266497.
    PubMed    


  16. CHANDRA DEB L, Hove H, Miller TK, Pinks K, et al
    Epidemiology of Hepatitis C virus infection among incarcerated populations in North Dakota.
    PLoS One. 2022;17:e0266047.
    PubMed     Abstract available


  17. ROJAS ROJAS T, Poizot-Martin I, Rey D, Duvivier C, et al
    Incidence of cervical, breast and colorectal cancers between 2010 and 2015 in people living with HIV in France.
    PLoS One. 2022;17:e0261069.
    PubMed     Abstract available


  18. SEYOUM E, Demissie M, Worku A, Mulu A, et al
    HIV, hepatitis B virus, and hepatitis C virus co-infection among HIV positives in antiretroviral treatment program in selected hospitals in Addis Ababa: A retrospective cross-sectional study.
    PLoS One. 2022;17:e0267230.
    PubMed     Abstract available


  19. AUMA AWN, Kowal C, Shive CL, Lange A, et al
    Transient elastography score is elevated during rheumatoid factor-positive chronic hepatitis C virus infection and rheumatoid factor decline is highly variable over the course of direct-acting antiviral therapy.
    PLoS One. 2022;17:e0267512.
    PubMed     Abstract available


  20. MABUNDA N, Augusto O, Zicai AF, Duaja A, et al
    Nucleic acid testing identifies high prevalence of blood borne viruses among approved blood donors in Mozambique.
    PLoS One. 2022;17:e0267472.
    PubMed     Abstract available


  21. TAHERKHANI R, Farshadpour F
    Prevalence, genotype distribution and mutations of hepatitis B virus and the associated risk factors among pregnant women residing in the northern shores of Persian Gulf, Iran.
    PLoS One. 2022;17:e0265063.
    PubMed     Abstract available


  22. FACENTE SN, Grinstein R, Bruhn R, Kaidarova Z, et al
    Hepatitis C prevalence and key population size estimate updates in San Francisco: 2015 to 2019.
    PLoS One. 2022;17:e0267902.
    PubMed     Abstract available


  23. MANZOOR S, Khalid M, Idrees M
    P2X4 receptors mediate induction of antioxidants, fibrogenic cytokines and ECM transcripts; in presence of replicating HCV in in vitro setting: An insight into role of P2X4 in fibrosis.
    PLoS One. 2022;17:e0259727.
    PubMed     Abstract available


  24. BATSAIKHAN B, Huang CI, Yeh ML, Huang CF, et al
    Persistent cryoglobulinemia after antiviral treatment is associated with advanced fibrosis in chronic hepatitis C patients.
    PLoS One. 2022;17:e0268180.
    PubMed     Abstract available


  25. O'DONNELL A, Pham N, Battisti L, Epstein R, et al
    Estimating the causal effect of treatment with direct-acting antivirals on kidney function among individuals with hepatitis C virus infection.
    PLoS One. 2022;17:e0268478.
    PubMed     Abstract available


  26. MARQUEZ LK, Ingiliz P, Boesecke C, Krznaric I, et al
    Establishing a framework towards monitoring HCV microelimination among men who have sex with men living with HIV in Germany: A modeling analysis.
    PLoS One. 2022;17:e0267853.
    PubMed     Abstract available


  27. ULLAH A, Yu X, Odenthal M, Meemboor S, et al
    Circulating microRNA-122 in HCV cirrhotic patients with high frequency of genotype 3.
    PLoS One. 2022;17:e0268526.
    PubMed     Abstract available


  28. BOFF DA COSTA R, Boff Costa M, Longo L, Miotto DE, et al
    Correction: Direct antiviral agents for hepatitis C and drug interaction risk: A retrospective cohort study with real and simulated data on medication interaction, prevalence of comorbidities and comedications.
    PLoS One. 2022;17:e0269049.
    PubMed     Abstract available


  29. KENFACK-MOMO R, Kenmoe S, Takuissu GR, Ebogo-Belobo JT, et al
    Epidemiology of hepatitis B virus and/or hepatitis C virus infections among people living with human immunodeficiency virus in Africa: A systematic review and meta-analysis.
    PLoS One. 2022;17:e0269250.
    PubMed     Abstract available


  30. CHUAYPEN N, Siripongsakun S, Hiranrat P, Tanpowpong N, et al
    Improvement of liver fibrosis, but not steatosis, after HCV eradication as assessment by MR-based imaging: Role of metabolic derangement and host genetic variants.
    PLoS One. 2022;17:e0269641.
    PubMed     Abstract available


  31. MADEIRA F, Costa-Lopes R, Do Bu EA, Tato Marinho R, et al
    The role of stereotypical information on medical judgements for black and white patients.
    PLoS One. 2022;17:e0268888.
    PubMed     Abstract available


  32. RAU M, Buggisch P, Mauss S, Boeker KHW, et al
    Prognostic impact of steatosis in the clinical course of chronic HCV infection-Results from the German Hepatitis C-Registry.
    PLoS One. 2022;17:e0264741.
    PubMed     Abstract available


  33. CHEN YC, Wang HW, Huang YT, Jiang MY, et al
    Association of hepatitis C virus infection status and genotype with kidney disease risk: A population-based cross-sectional study.
    PLoS One. 2022;17:e0271197.
    PubMed     Abstract available


  34. CAIROLI V, De Matteo E, Casciato P, Ameigeiras B, et al
    The performance of soluble CD163 as a non-invasive biomarker of liver damage in chronically HCV and HCV/HIV infected subjects.
    PLoS One. 2022;17:e0270911.
    PubMed     Abstract available


  35. SHIRAI K, Hikita H, Sakane S, Narumi R, et al
    Serum amyloid P component and pro-platelet basic protein in extracellular vesicles or serum are novel markers of liver fibrosis in chronic hepatitis C patients.
    PLoS One. 2022;17:e0271020.
    PubMed     Abstract available


  36. SAHIBZADA KI, Ganova-Raeva L, Dimitrova Z, Ramachandran S, et al
    Hepatitis C virus transmission cluster among injection drug users in Pakistan.
    PLoS One. 2022;17:e0270910.
    PubMed     Abstract available


  37. MATA-MARIN JA, de Pablos-Leal AA, Mauss S, Arroyo-Anduiza CI, et al
    Risk factors for HCV transmission in HIV-positive men who have sex with men in Mexico.
    PLoS One. 2022;17:e0269977.
    PubMed     Abstract available


  38. LAHOOD A, Rahman R, McKenna L, Frick M, et al
    Comparing timelines and evidence available to support new TB, HIV, and HCV drug approvals: The same, only different.
    PLoS One. 2022;17:e0271102.
    PubMed     Abstract available


  39. VAKILI J, Sizemore L, Rebeiro PF, Tyndall B, et al
    Assessment of Tennessee's county-level vulnerability to hepatitis C virus and HIV outbreaks using socioeconomic, healthcare, and substance use indicators.
    PLoS One. 2022;17:e0270891.
    PubMed     Abstract available


  40. SCHORR O, Blach S, Thurnheer C, Ruis C, et al
    Modelling the microelimination of chronic hepatitis C in the canton of Bern, Switzerland: Reaching the Swiss Hepatitis Strategy goals despite the impact of the COVID 19 pandemic.
    PLoS One. 2022;17:e0272518.
    PubMed     Abstract available


  41. LU YH, Lu CK, Chen CH, Hsieh YY, et al
    Comparison of 8- versus 12-weeks of glecaprevir/pibrentasvir for Taiwanese patients with hepatitis C and compensated cirrhosis in a real-world setting.
    PLoS One. 2022;17:e0272567.
    PubMed     Abstract available


  42. TESFU MA, Belay NB, Habtemariam TT
    Co-infection of HIV or HCV among HBsAg positive delivering mothers and its associated factors in governmental hospitals in Addis Ababa, Ethiopia: A cross-sectional study.
    PLoS One. 2022;17:e0273300.
    PubMed     Abstract available


  43. STOPKA TJ, Yaghi O, Li M, Paintsil E, et al
    Molecular and spatial epidemiology of HCV among people who inject drugs in Boston, Massachusetts.
    PLoS One. 2022;17:e0266216.
    PubMed     Abstract available


  44. CELESTE-VILLALVIR A, Wilkerson JM, Markham C, Rodriguez L, et al
    A qualitative investigation of organizational challenges and facilitators to screening individuals experiencing homelessness for hepatitis C virus (HCV) in Houston, Texas.
    PLoS One. 2022;17:e0273302.
    PubMed     Abstract available


  45. BEHMARD E, Abdulabbas HT, Abdalkareem Jasim S, Najafipour S, et al
    Design of a novel multi-epitope vaccine candidate against hepatitis C virus using structural and nonstructural proteins: An immunoinformatics approach.
    PLoS One. 2022;17:e0272582.
    PubMed     Abstract available


  46. NARTEY YA, Antwi SO, Bockarie AS, Hiebert L, et al
    Mortality burden due to liver cirrhosis and hepatocellular carcinoma in Ghana; prevalence of risk factors and predictors of poor in-hospital survival.
    PLoS One. 2022;17:e0274544.
    PubMed     Abstract available


  47. KACEM M, Dhouib W, Bennasrallah C, Zemni I, et al
    Occupational exposure to hepatitis C virus infection and associated factors among healthcare workers in Fattouma Bourguiba University Hospital, Tunisia.
    PLoS One. 2022;17:e0274609.
    PubMed     Abstract available


  48. YOKOKAWA H, Shinohara M, Teraoka Y, Imamura M, et al
    Patient-derived monoclonal antibody neutralizes HCV infection in vitro and vivo without generating escape mutants.
    PLoS One. 2022;17:e0274283.
    PubMed     Abstract available


  49. LEE AW, Jacobs W, Tran M, Nguyen B, et al
    Sociodemographic characteristics associated with hepatitis C virus infection in Vietnamese Americans: A cross-sectional analysis of community screening data.
    PLoS One. 2022;17:e0275210.
    PubMed     Abstract available


  50. IBRAHIM ST, Abdelhamid MR, Lewis N, Baddour N, et al
    Role of fluid-phase complement system regulation in the development of hepatitis C virus-associated glomerulonephritis.
    PLoS One. 2022;17:e0276017.
    PubMed     Abstract available


  51. EL SHEREF SEDM, Afify S, Berengy MS
    Clinical characteristics and predictors of esophagogastric variceal bleeding among patients with HCV-induced liver cirrhosis: An observational comparative study.
    PLoS One. 2022;17:e0275373.
    PubMed     Abstract available


  52. BADSHAH Y, Shabbir M, Khan K, Fatima M, et al
    Manipulation of Interleukin-6 (IL-6) and Transforming Growth Factor Beta-1(TGFbeta-1) towards viral induced liver cancer pathogenesis.
    PLoS One. 2022;17:e0275834.
    PubMed     Abstract available


  53. YAMATAKA K, Chu PS, Koda Y, Taniki N, et al
    Dynamics of type IV collagen 7S fragment on eradication of HCV with direct antiviral agents: Prognostic and metabolomic impacts.
    PLoS One. 2022;17:e0276925.
    PubMed     Abstract available


  54. CHIA CT, Bender AT, Lillis L, Sullivan BP, et al
    Rapid detection of hepatitis C virus using recombinase polymerase amplification.
    PLoS One. 2022;17:e0276582.
    PubMed     Abstract available


  55. YEE LM, Shah SK, Grobman WA, Labellarte PZ, et al
    Identifying barriers and facilitators of the inclusion of pregnant individuals in hepatitis C treatment programs in the United States.
    PLoS One. 2022;17:e0277987.
    PubMed     Abstract available


  56. ABU EL-MAKAREM MA, Kamel MF, Mohamed AA, Ali HA, et al
    Down-regulation of hepatic expression of GHR/STAT5/IGF-1 signaling pathway fosters development and aggressiveness of HCV-related hepatocellular carcinoma: Crosstalk with Snail-1 and type 2 transforming growth factor-beta receptor.
    PLoS One. 2022;17:e0277266.
    PubMed     Abstract available


  57. NAGUIB M, Abdel-Razek W, Estaphan S, Abdelsameea E, et al
    Impact of prothrombin and factor V Leiden mutations on the progression of fibrosis in patients with chronic hepatitis C.
    PLoS One. 2022;17:e0276592.
    PubMed     Abstract available


    January 2021
  58. HEFFERNAN A, Ma Y, Nayagam S, Chan P, et al
    Economic and epidemiological evaluation of interventions to reduce the burden of hepatitis C in Yunnan province, China.
    PLoS One. 2021;16:e0245288.
    PubMed     Abstract available


  59. HUANG YC, Huang CF, Liu SF, Liu HY, et al
    The performance of HCV GT plus RUO reagent in determining Hepatitis C virus genotypes in Taiwan.
    PLoS One. 2021;16:e0246376.
    PubMed     Abstract available


  60. LIN CP, Liang PC, Huang CI, Yeh ML, et al
    Concordance of SVR12, SVR24 and SVR durability in Taiwanese chronic hepatitis C patients with direct-acting antivirals.
    PLoS One. 2021;16:e0245479.
    PubMed     Abstract available


  61. BAKER JD, Uhrich RL, Kraemer GC, Love JE, et al
    A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV2 main protease.
    PLoS One. 2021;16:e0245962.
    PubMed     Abstract available


  62. BOFF DA COSTA R, Boff Costa M, Longo L, Miotto DE, et al
    Direct antiviral agents for hepatitis C and drug interaction risk: A retrospective cohort study with real and simulated data on medication interaction, prevalence of comorbidities and comedications.
    PLoS One. 2021;16:e0245767.
    PubMed     Abstract available


  63. KWON JA, Chambers GM, Luciani F, Zhang L, et al
    Hepatitis C treatment strategies in prisons: A cost-effectiveness analysis.
    PLoS One. 2021;16:e0245896.
    PubMed     Abstract available


  64. MAJD JABBARI S, Maajani K, Merat S, Poustchi H, et al
    An updated systematic review and meta-analysis on efficacy of Sofosbuvir in treating hepatitis C-infected patients with advanced chronic kidney disease.
    PLoS One. 2021;16:e0246594.
    PubMed     Abstract available


  65. ANWAR WA, El Gaafary M, Girgis SA, Rafik M, et al
    Hepatitis C virus infection and risk factors among patients and health-care workers of Ain Shams University hospitals, Cairo, Egypt.
    PLoS One. 2021;16:e0246836.
    PubMed     Abstract available


  66. GRUBYTE S, Urboniene J, Nedzinskiene L, Jelinskaite A, et al
    Prevalence, incidence and residual risk of transfusion transmitted viruses (HBV, HCV and HIV infections) in Lithuanian blood donors from 2004 to 2018: The incidence/window-period model study.
    PLoS One. 2021;16:e0246704.
    PubMed     Abstract available


  67. MUHLBACHER AC, Sadler A
    Comment on the paper "Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results".
    PLoS One. 2021;16:e0245480.
    PubMed    


  68. METWALLY AM, Elmosalami DM, Elhariri H, El Etreby LA, et al
    Accelerating Hepatitis C virus elimination in Egypt by 2030: A national survey of communication for behavioral development as a modelling study.
    PLoS One. 2021;16:e0242257.
    PubMed     Abstract available


  69. HO H, Janjua NZ, McGrail KM, Harrison M, et al
    The impact of public coverage of newer hepatitis C medications on utilization, adherence, and costs in British Columbia.
    PLoS One. 2021;16:e0247843.
    PubMed     Abstract available


  70. RAJHI M, Haddad-Boubaker S, Chouikha A, Bourquain D, et al
    Identification of two novel hepatitis C virus subtype 2 from Tunisia (2v and 2w).
    PLoS One. 2021;16:e0248249.
    PubMed     Abstract available


  71. MCINTOSH AT, Wei R, Ahn J, Aouizerat BE, et al
    A genomic variant of ALPK2 is associated with increased liver fibrosis risk in HIV/HCV coinfected women.
    PLoS One. 2021;16:e0247277.
    PubMed     Abstract available


  72. SUENAGA R, Suka M, Hirao T, Hidaka I, et al
    Cost-effectiveness of a "treat-all" strategy using Direct-Acting Antivirals (DAAs) for Japanese patients with chronic hepatitis C genotype 1 at different fibrosis stages.
    PLoS One. 2021;16:e0248748.
    PubMed     Abstract available


  73. HERNANDEZ CJ, Trujillo D, Sicro S, Meza J, et al
    High hepatitis C virus seropositivity, viremia, and associated risk factors among trans women living in San Francisco, California.
    PLoS One. 2021;16:e0249219.
    PubMed     Abstract available


  74. TONEN-WOLYEC S, Djang'eing'a RM, Batina-Agasa S, Kayembe Tshilumba C, et al
    Self-testing for HIV, HBV, and HCV using finger-stick whole-blood multiplex immunochromatographic rapid test: A pilot feasibility study in sub-Saharan Africa.
    PLoS One. 2021;16:e0249701.
    PubMed     Abstract available


  75. MIRZAZADEH A, Chen YH, Lin J, Burk K, et al
    Progress toward closing gaps in the hepatitis C virus cascade of care for people who inject drugs in San Francisco.
    PLoS One. 2021;16:e0249585.
    PubMed     Abstract available


  76. AHMED HR, Waly NGFM, Abd El-Baky RM, Yahia R, et al
    Distribution of naturally -occurring NS5B resistance-associated substitutions in Egyptian patients with chronic Hepatitis C.
    PLoS One. 2021;16:e0249770.
    PubMed     Abstract available


  77. PONNUVEL S, Fletcher GJ, Anantharam R, Varughese S, et al
    Clinical utility of hepatitis C virus core antigen (HCVcAg) assay to identify active HCV infection in hemodialysis and renal transplant patients.
    PLoS One. 2021;16:e0250263.
    PubMed     Abstract available


  78. PALAYEW A, Schmidt AM, Saeed S, Cooper CL, et al
    Estimating an individual-level deprivation index for HIV/HCV coinfected persons in Canada.
    PLoS One. 2021;16:e0249836.
    PubMed     Abstract available


  79. KAARTINEN K, Vuoti S, Honkanen E, Loyttyniemi E, et al
    Tubular cell damage may be the earliest sign of renal extrahepatic manifestation caused by Hepatitis C.
    PLoS One. 2021;16:e0251392.
    PubMed     Abstract available


  80. LEE CY, Wu PH, Lu MW, Chen TC, et al
    High prevalence of unawareness of HCV infection status among both HCV-seronegative and seropositive people living with human immunodeficiency virus in Taiwan.
    PLoS One. 2021;16:e0251158.
    PubMed     Abstract available


  81. BUGGISCH P, Heiken H, Mauss S, Weber B, et al
    Barriers to initiation of hepatitis C virus therapy in Germany: A retrospective, case-controlled study.
    PLoS One. 2021;16:e0250833.
    PubMed     Abstract available


  82. IREKEOLA AA, Malek NA, Wada Y, Mustaffa N, et al
    Prevalence of HCV genotypes and subtypes in Southeast Asia: A systematic review and meta-analysis.
    PLoS One. 2021;16:e0251673.
    PubMed     Abstract available


  83. BOBARDT M, Ramirez CM, Baum MM, Ure D, et al
    The combination of the NS5A and cyclophilin inhibitors results in an additive anti-HCV inhibition in humanized mice without development of resistance.
    PLoS One. 2021;16:e0251934.
    PubMed     Abstract available


  84. DIDIYA R, Gyenwali D, Pokhrel TN, Devkota S, et al
    Community led testing among people who inject drugs: A community centered model to find new cases of HIV and Hepatitis C in Nepal.
    PLoS One. 2021;16:e0252490.
    PubMed     Abstract available


  85. WURCEL AG, Reyes J, Zubiago J, Koutoujian PJ, et al
    "I'm not gonna be able to do anything about it, then what's the point?": A broad group of stakeholders identify barriers and facilitators to HCV testing in a Massachusetts jail.
    PLoS One. 2021;16:e0250901.
    PubMed     Abstract available


  86. PARK JS, Wong J, Cohen H
    Hepatitis C virus screening of high-risk patients in a community hospital emergency department: Retrospective review of patient characteristics and future implications.
    PLoS One. 2021;16:e0252976.
    PubMed     Abstract available


  87. WYNN A, Tweeten S, McDonald E, Wooten W, et al
    The estimated hepatitis C seroprevalence and key population sizes in San Diego in 2018.
    PLoS One. 2021;16:e0251635.
    PubMed     Abstract available


  88. FLEISHER I, Geboy AG, Nichols W, Desale S, et al
    HIV testing in patients who are HCV positive: Compliance with CDC guidelines in a large healthcare system.
    PLoS One. 2021;16:e0252412.
    PubMed     Abstract available


  89. GAHRTON C, Hakansson A, Kaberg M, Jerkeman A, et al
    Mortality among amphetamine users with hepatitis C virus infection: A nationwide study.
    PLoS One. 2021;16:e0253710.
    PubMed     Abstract available


  90. TORO DM, Ramasawmy R, Silva Neto PV, Pereira GL, et al
    Inflammasome genes polymorphisms may influence the development of hepatitis C in the Amazonas, Brazil.
    PLoS One. 2021;16:e0253470.
    PubMed     Abstract available


  91. RAHMAN S, Wathington D, Waterboer T, Pawlita M, et al
    Seroprevalence of Chlamydia trachomatis, herpes simplex 2, Epstein-Barr virus, hepatitis C and associated factors among a cohort of men ages 18-70 years from three countries.
    PLoS One. 2021;16:e0253005.
    PubMed     Abstract available


  92. LIU HY, Lin YH, Lin PJ, Tsai PC, et al
    Anti-HCV antibody titer highly predicts HCV viremia in patients with hepatitis B virus dual-infection.
    PLoS One. 2021;16:e0254028.
    PubMed     Abstract available


  93. LLORENS-REVULL M, Costafreda MI, Rico A, Guerrero-Murillo M, et al
    Partial restoration of immune response in Hepatitis C patients after viral clearance by direct-acting antiviral therapy.
    PLoS One. 2021;16:e0254243.
    PubMed     Abstract available


  94. BLOOM DE, Khoury A, Srinivasan V
    Estimating the net value of treating hepatitis C virus using sofosbuvir-velpatasvir in India.
    PLoS One. 2021;16:e0252764.
    PubMed     Abstract available


  95. PRENTOE J, Janitzek CM, Velazquez-Moctezuma R, Goksoyr L, et al
    Antigenic and immunogenic evaluation of permutations of soluble hepatitis C virus envelope protein E2 and E1 antigens.
    PLoS One. 2021;16:e0255336.
    PubMed     Abstract available


  96. DEFANTE FERRETO LE, Guedes S, Braz Pauli F, Soligo Rovani S, et al
    Seroprevalence and associated factors of HIV and Hepatitis C in Brazilian high-security prisons: A state-wide epidemiological study.
    PLoS One. 2021;16:e0255173.
    PubMed     Abstract available


  97. SINN DH, Kang D, Hong YS, Koh KC, et al
    Prior antiviral treatment and mortality among patients with hepatitis C virus-related hepatocellular carcinoma: A national cohort study.
    PLoS One. 2021;16:e0255624.
    PubMed     Abstract available


  98. YUNIHASTUTI E, Hariyanto R, Sulaiman AS, Harimurti K, et al
    Hepatitis C continuum of care: Experience of integrative hepatitis C treatment within a human immunodeficiency virus clinic in Indonesia.
    PLoS One. 2021;16:e0256164.
    PubMed     Abstract available


  99. AHSAN A, Dar S, Hassan F, Ghafoor F, et al
    Characterization of linear epitope specificity of antibodies potentially contributing to spontaneous clearance of hepatitis C virus.
    PLoS One. 2021;16:e0256816.
    PubMed     Abstract available


  100. KOBAYASHI H, Joshita S, Akahane Y, Matsuzaki K, et al
    Protocol: Prospective observational study aiming for micro-elimination of hepatitis C virus in Nagawa town: The Nagawa Project.
    PLoS One. 2021;16:e0256711.
    PubMed     Abstract available


  101. CHEN YC, Li CH, Ko PH, Lee CC, et al
    Neutrophil gelatinase-associated lipocalin partly reflects the dynamic changes of renal function among chronic hepatitis C patients receiving direct-acting antivirals.
    PLoS One. 2021;16:e0256505.
    PubMed     Abstract available


  102. ATSUKAWA M, Tsubota A, Kondo C, Uchida-Kobayashi S, et al
    A novel noninvasive formula for predicting cirrhosis in patients with chronic hepatitis C.
    PLoS One. 2021;16:e0257166.
    PubMed     Abstract available


  103. KWON JA, Dore GJ, Hajarizadeh B, Alavi M, et al
    Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications.
    PLoS One. 2021;16:e0257369.
    PubMed     Abstract available


  104. MIZUNO K, Haga H, Okumoto K, Hoshikawa K, et al
    Intrahepatic distribution of nerve fibers and alterations due to fibrosis in diseased liver.
    PLoS One. 2021;16:e0249556.
    PubMed     Abstract available


  105. KONG L, Karns R, Shata MTM, Brown JL, et al
    The synthetic opioid fentanyl enhances viral replication in vitro.
    PLoS One. 2021;16:e0249581.
    PubMed     Abstract available


  106. WAKABAYASHI SI, Joshita S, Kimura K, Motoki H, et al
    Protocol: Prospective observational study investigating the prevalence and clinical outcome of portopulmonary hypertension in Japanese patients with chronic liver disease.
    PLoS One. 2021;16:e0249435.
    PubMed     Abstract available


  107. LEE SO, Lee JE, Lee S, Lee SH, et al
    Prevalence and patterns of illicit drug use in people with human immunodeficiency virus infection in Korea.
    PLoS One. 2021;16:e0249361.
    PubMed     Abstract available


  108. MAZHAR MKA, Finger F, Evers ES, Kuehne A, et al
    An outbreak of acute jaundice syndrome (AJS) among the Rohingya refugees in Cox's Bazar, Bangladesh: Findings from enhanced epidemiological surveillance.
    PLoS One. 2021;16:e0250505.
    PubMed     Abstract available


  109. AFANEH H, Straif-Bourgeois S, Oral E, Wennerstrom A, et al
    Louisiana Medicaid access for treatment and care for hepatitis C virus (LA-MATCH) project: A cross-sectional study protocol.
    PLoS One. 2021;16:e0257437.
    PubMed     Abstract available


  110. SAINE ME, Szymczak JE, Moore TM, Bamford LP, et al
    The impact of disease-related knowledge on perceptions of stigma among patients with Hepatitis C Virus (HCV) infection.
    PLoS One. 2021;16:e0258143.
    PubMed     Abstract available


  111. ELKARANSHAWY HA, Ezzat HM, Ibrahim NN
    Lyapunov function and global asymptotic stability for a new multiscale viral dynamics model incorporating the immune system response: Implemented upon HCV.
    PLoS One. 2021;16:e0257975.
    PubMed     Abstract available


  112. MREMI A, Yahaya JJ, Nyindo M, Mollel E, et al
    Transfusion-Transmitted Infections and associated risk factors at the Northern Zone Blood Transfusion Center in Tanzania: A study of blood donors between 2017 and 2019.
    PLoS One. 2021;16:e0249061.
    PubMed     Abstract available


  113. KLOK S, van Dulm E, Boyd A, Generaal E, et al
    Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) infections among undocumented migrants and uninsured legal residents in the Netherlands: A cross-sectional study, 2018-2019.
    PLoS One. 2021;16:e0258932.
    PubMed     Abstract available


  114. ADANE T, Getawa S
    The prevalence and associated factors of hepatitis B and C virus in hemodialysis patients in Africa: A systematic review and meta-analysis.
    PLoS One. 2021;16:e0251570.
    PubMed     Abstract available


  115. FERRETO LED, Guedes SJKO, Pauli FB, Rovani SS, et al
    Correction: Seroprevalence and associated factors of HIV and Hepatitis C in Brazilian high-security prisons: A state-wide epidemiological study.
    PLoS One. 2021;16:e0260179.
    PubMed     Abstract available


  116. ISRAR M, Ali F, Nawaz A, Idrees M, et al
    Seroepidemiology and associated risk factors of hepatitis B and C virus infections among pregnant women attending maternity wards at two hospitals in Swabi, Khyber Pakhtunkhwa, Pakistan.
    PLoS One. 2021;16:e0255189.
    PubMed     Abstract available


  117. TOWNSHEND-BULSON L, Roik E, Barbour Y, Bruden DJT, et al
    The Alaska Native/American Indian experience of hepatitis C treatment with sofosbuvir-based direct-acting antivirals.
    PLoS One. 2021;16:e0260970.
    PubMed     Abstract available


  118. GARCIA-HEROLA A, Dominguez-Hernandez R, Casado MA
    Clinical and economic impact of an alert system in primary care for the detection of patients with chronic hepatitis C.
    PLoS One. 2021;16:e0260608.
    PubMed     Abstract available


  119. NERSESOV A, Gusmanov A, Crape B, Junusbekova G, et al
    Seroprevalence and risk factors for hepatitis B and hepatitis C in three large regions of Kazakhstan.
    PLoS One. 2021;16:e0261155.
    PubMed     Abstract available


  120. KAMALI I, Barnhart DA, Ndahimana JD, Noor K, et al
    Prevalence and associated risk factors for hepatitis B and C viruses among refugee populations living in Mahama, Rwanda: A cross-sectional study.
    PLoS One. 2021;16:e0257917.
    PubMed     Abstract available


  121. BITTY-ANDERSON AM, Ferre V, Gbeasor-Komlanvi FA, Tchankoni MK, et al
    Prevalence of hepatitis B and C among female sex workers in Togo, West Africa.
    PLoS One. 2021;16:e0259891.
    PubMed     Abstract available


    January 2020
  122. GANDJOUR A
    Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results.
    PLoS One. 2020;15:e0236543.
    PubMed     Abstract available


  123. OYAMA M, Ohnuki Y, Inoue M, Uruha A, et al
    HLA-DRB1 allele and autoantibody profiles in Japanese patients with inclusion body myositis.
    PLoS One. 2020;15:e0237890.
    PubMed     Abstract available


  124. AMORAS EDSG, Monteiro Gomes ST, Freitas Queiroz MA, de Araujo MSM, et al
    Intrahepatic interleukin 10 expression modulates fibrinogenesis during chronic HCV infection.
    PLoS One. 2020;15:e0241199.
    PubMed     Abstract available


  125. GALLACH M, Vergara M, Pedro da Costa J, Miquel M, et al
    Correction: Impact of treatment with direct-acting antivirals on anxiety and depression in chronic hepatitis C.
    PLoS One. 2020;15:e0241559.
    PubMed     Abstract available


  126. CARDONA-ARIAS JA, Correa JCC, Higuita-Gutierrez LF
    Prevalence of hepatitis B/C viruses and associated factors in key groups attending a health services institution in Colombia, 2019.
    PLoS One. 2020;15:e0238655.
    PubMed     Abstract available


  127. HAGA H, Sato H, Koseki A, Saito T, et al
    A machine learning-based treatment prediction model using whole genome variants of hepatitis C virus.
    PLoS One. 2020;15:e0242028.
    PubMed     Abstract available


  128. JAVANBAKHT M, Archer R, Klausner J
    Will prior health insurance authorization for medications continue to hinder hepatitis C treatment delivery in the United States? Perspectives from hepatitis C treatment providers in a large urban healthcare system.
    PLoS One. 2020;15:e0241615.
    PubMed     Abstract available


  129. SEMMO N, Mullhaupt B, Ruckstuhl L, Magenta L, et al
    A prospective, multicenter, post-marketing observational study to measure the quality of life of HCV genotype 1 infected, treatment naive patients suffering from fatigue and receiving 3D regimen: The HEMATITE study.
    PLoS One. 2020;15:e0241267.
    PubMed     Abstract available


  130. LEE JJ, Wei YJ, Lin MY, Niu SW, et al
    The applicability of non-invasive methods for assessing liver fibrosis in hemodialysis patients with chronic hepatitis C.
    PLoS One. 2020;15:e0242601.
    PubMed     Abstract available


  131. PAPALUCA T, Craigie A, McDonald L, Edwards A, et al
    Non-invasive fibrosis algorithms are clinically useful for excluding cirrhosis in prisoners living with hepatitis C.
    PLoS One. 2020;15:e0242101.
    PubMed     Abstract available


  132. JIANG K, Mohammad MK, Dar WA, Kong J, et al
    Quantitative assessment of liver fibrosis by digital image analysis reveals correlation with qualitative clinical fibrosis staging in liver transplant patients.
    PLoS One. 2020;15:e0239624.
    PubMed     Abstract available


  133. PATIL S, Rao A, Pathak P, Kurle S, et al
    Unsterile injection equipment associated with HIV outbreak and an extremely high prevalence of HCV-A case-control investigation from Unnao, India.
    PLoS One. 2020;15:e0243534.
    PubMed     Abstract available


  134. VETTER BN, Ongarello S, Tyshkovskiy A, Alkhazashvili M, et al
    Sensitivity and specificity of rapid hepatitis C antibody assays in freshly collected whole blood, plasma and serum samples: A multicentre prospective study.
    PLoS One. 2020;15:e0243040.
    PubMed     Abstract available


  135. AKIYAMA MJ, Ross J, Rimawi F, Fox A, et al
    Knowledge, attitudes, and acceptability of direct-acting antiviral hepatitis C treatment among people incarcerated in jail: A qualitative study.
    PLoS One. 2020;15:e0242623.
    PubMed     Abstract available


  136. SAZZAD HMS, McCredie L, Treloar C, Lloyd AR, et al
    Violence and hepatitis C transmission in prison-A modified social ecological model.
    PLoS One. 2020;15:e0243106.
    PubMed     Abstract available


  137. SOHOLM J, Hansen JF, Mossner B, Roge BT, et al
    Low incidence of HCC in chronic hepatitis C patients with pretreatment liver stiffness measurements below 17.5 kilopascal who achieve SVR following DAAs.
    PLoS One. 2020;15:e0243725.
    PubMed     Abstract available


  138. ABE K, Wakabayashi H, Nakayama H, Suzuki T, et al
    Factors associated with hepatocellular carcinoma occurrence after HCV eradication in patients without cirrhosis or with compensated cirrhosis.
    PLoS One. 2020;15:e0243473.
    PubMed     Abstract available


  139. BEKKI S, Hashimoto S, Yamasaki K, Komori A, et al
    Serum kynurenine levels are a novel biomarker to predict the prognosis of patients with hepatocellular carcinoma.
    PLoS One. 2020;15:e0241002.
    PubMed     Abstract available


  140. PEARCE ME, Yu A, Alvarez M, Bartlett SR, et al
    Prenatal hepatitis C screening, diagnoses, and follow-up testing in British Columbia, 2008-2019.
    PLoS One. 2020;15:e0244575.
    PubMed     Abstract available


  141. KHLAIPHUENGSIN A, Chuaypen N, Sodsai P, Reantragoon R, et al
    Successful direct-acting antiviral therapy improves circulating mucosal-associated invariant T cells in patients with chronic HCV infection.
    PLoS One. 2020;15:e0244112.
    PubMed     Abstract available


  142. MIGITA K, Nakamura M, Aiba Y, Kozuru H, et al
    Association of soluble T cell immunoglobulin domain and mucin-3 (sTIM-3) and mac-2 binding protein glycosylation isomer (M2BPGi) in patients with autoimmune hepatitis.
    PLoS One. 2020;15:e0238540.
    PubMed     Abstract available


  143. POURCHER V, Gourmelen J, Bureau I, Bouee S, et al
    Comorbidities in people living with HIV: An epidemiologic and economic analysis using a claims database in France.
    PLoS One. 2020;15:e0243529.
    PubMed     Abstract available


  144. LAWAL MA, Adeniyi OF, Akintan PE, Salako AO, et al
    Prevalence of and risk factors for hepatitis B and C viral co-infections in HIV infected children in Lagos, Nigeria.
    PLoS One. 2020;15:e0243656.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis C is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: